Dopamine Hydrochloride Injection

The effect of stimulating adrenergic receptors in the sympathetic nervous system and dopamine receptors in the kidney, mesentery, coronary artery, and cerebral artery is dose-dependent. 1. At low doses (0.5-2 μg/kg per minute based on body weight), it mainly acts on dopamine receptors, dilating the blood vessels of the kidney and mesenteric artery, increasing renal blood flow and glomerular filtration rate, and increasing urine volume and sodium excretion; 2. At small to medium doses (2-10 μg/kg per minute based on body weight), it can directly stimulate β1 receptors and indirectly promote the release of norepinephrine from storage sites, exerting positive stress on the myocardium, increasing myocardial contractility and stroke volume, and ultimately increasing cardiac output, systolic blood pressure, and possibly pulse pressure, with no change or slight increase in diastolic blood pressure, peripheral total resistance often unchanged, and coronary blood flow and oxygen consumption improved; 3. At high doses (greater than 10 μg/kg per minute based on body weight), it stimulates α receptors, leading to increased peripheral vascular resistance, renal vasoconstriction, and reduced renal blood flow and urine volume. Due to the increase in cardiac output and peripheral vascular resistance, both systolic and diastolic blood pressures increase. (1) It stimulates the cardiac β1 receptors and has a much stronger effect on increasing myocardial contractility; (2) It increases the blood flow to the kidneys and mesentery, which can prevent the malignant development of shock caused by ischemia of these organs. Under the same condition of increasing myocardial contractility, the effects of causing arrhythmias and increasing myocardial oxygen consumption are weaker. In short, dopamine is particularly suitable for shock patients with weakened myocardial contractility, decreased urine output, and replenished blood volume.

The chemical name of this product is: 4-(2-aminoethyl)-1,2-benzenediol hydrochloride

This product is a colorless clear liquid

It is suitable for shock syndrome caused by myocardial infarction, trauma, endotoxin sepsis, heart surgery, renal failure, congestive heart failure, etc.; shock cannot be corrected after blood volume supplementation, especially shock with oliguria and normal or low peripheral vascular resistance. Because this product can increase cardiac output, it is also used for heart failure that is ineffective with digitalis and diuretics.

Commonly used doses for adults are intravenous injections, starting at 1-5 μg/kg per minute based on body weight, and increasing at a rate of 1-4 μg/kg per minute within 10 minutes to achieve maximum efficacy. For chronic refractory heart failure, when starting intravenous drip, gradually increase by 0.5-2 μg/kg per minute based on body weight. For most patients, 1-3 μg/kg/min will be effective. For patients with occlusive vascular lesions, start with intravenous drip at 1 μg/kg/min, gradually increase to 5-10 μg/kg/min, until 20 μg/kg/min, to achieve the most satisfactory effect. For critical cases, first drip at 5 μg/kg/min, then increase at 5-10 μg/kg/min to 20-50 μg/kg/min to achieve a satisfactory effect. Or add 20 mg of this product to 200-300 ml of 5% glucose injection and drip intravenously. Initially, drip at 75-100 μg/min. Later, depending on the blood pressure situation, the speed and concentration can be increased, but the maximum dose should not exceed 500 μg per minute.

Common symptoms include chest pain, dyspnea, palpitations, arrhythmia (especially with large doses), and general weakness; slow heartbeat, headache, nausea and vomiting are rare. Long-term use of large or small doses in patients with peripheral vascular disease may cause pain or coldness in the hands and feet; prolonged contraction of peripheral blood vessels may lead to local necrosis or gangrene; overdose may cause high blood pressure, in which case the drug should be discontinued and α-receptor blockers should be given if necessary.

It is contraindicated for those who are allergic to any ingredient of this product.

1. When used in combination with sodium nitroprusside, isoproterenol, and dobutamine, pay attention to changes in cardiac output, which will react differently than when this product is used alone. 2. When large doses of dopamine are used in combination with α-receptor blockers such as phenoxybenzamine, phentolamine, and tolazoline, the vasodilatory effect of the latter can be antagonized by the peripheral vasoconstrictive effect of this product. 3. When used in combination with general anesthetics (especially cyclopropane or halogenated hydrocarbons), the latter can make the myocardium abnormally sensitive to dopamine, causing ventricular arrhythmias. 4. When used in combination with β-receptor blockers, it can antagonize the effect of dopamine on the β1 receptors of the heart. 5. When used in combination with nitrates, it can weaken the anti-anginal effect of nitrates and the pressor effect of dopamine. 6. When used in combination with diuretics, on the one hand, because this product acts on dopamine receptors to dilate renal blood vessels, it increases renal blood flow and can increase the diuretic effect; on the other hand, this product itself has a direct diuretic effect. 7 When used with guanethidine, it can enhance the pressor effect of dopamine, weaken the antihypertensive effect of guanethidine, and lead to hypertension and arrhythmia. 8 When used simultaneously with tricyclic antidepressants, it may increase the cardiovascular effect of dopamine, causing arrhythmia, tachycardia, and hypertension. 9 When used together with monoamine oxidase inhibitors, it can prolong and enhance the effect of dopamine; it is known that this product is metabolized by monoamine oxidase. For patients who have received monoamine oxidase inhibitors 2-3 weeks before dopamine administration, the initial dose should be reduced to at least 1/10 of the usual dose. 10 Simultaneous intravenous injection with phenytoin sodium can produce hypotension and bradycardia. When using dopamine, if phenytoin sodium must be used for anticonvulsant treatment, the two drugs should be considered for alternating use.

Shade from light, store in a sealed container

2ml:20mg

Wuhan Jiu'an Pharmaceutical Co., Ltd.

• Founded in:

  1999-10-14

• Address:

  Wuhan Miaoshan Community Special No. 1 Wuhan Pharmaceutical Industrial Park

• Tax NO.:

  91420115717919268T

• Registered Funds:

  132.06 million yuan

• Website:

  Log in to view

• Email:

  Log in to view